Novartis presented positive primary endpoint data from the phase III NATALEE trial at the 2023 American Society of Clinical Oncology Annual Meeting.Â
Cartography Biosciences Inc. has entered a strategic collaboration agreement with Gilead Sciences Inc., to discover and develop therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer, adenocarcinoma.
AÂ common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.Â
Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
The Menarini Group and Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, will present updated results from phase Ib/II ELECTRA and ELEVATE clinical studies evaluating elacestrant (Orserdu) in combination with other treatments at the 2024 American Society of Clinical Oncology on June 2.Â
Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function, a UCLA-led study suggests.
Norman Wolmark, chairman of the NSABP Foundation Inc., and group chair and contact principal investigator of NRG Oncology, received the 2024 American Surgical Association Medallion for Advancement of Surgical Care at the American Surgical Association’s 144th annual meeting in Washington, DC.
When cancer breaches the brain, it can be difficult for treatment to follow.
All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30.
